Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2021
Price :
$35
*
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Atopic dermatitis; Eczema
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 12 Jun 2020 According to an Eli Lilly and Company media release, data from this study was presented at the American Academy of Dermatology 2020 Annual Meeting.
- 12 Jun 2020 Results published in the Eli Lilly and Company Media Release
- 26 Feb 2020 Results assessing efficacy and safety of lebrikizumab in adults with moderate to severe atopic dermatitis, published in the JAMA Dermatology.